Business
Nurix Therapeutics to Participate in the 4th Annual Targeted Protein Degradation Summit
SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation
About this update from Nurix Therapeutics, Inc.
[{"type":"text","content":"SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Nurix’s president and chief executive officer Arthur T. Sands, M.D., Ph.D., and Nurix’s chief scientific officer Gwenn M. Hansen, Ph.D., will participate in several sessions of the 4th Annual Targeted Protein Degradation (TPD) Summit, which will be held virtually October 26-29, 2021. Details of Nurix’s presentations: Tuesday, October 26Pre-Conference Workshop: TPD 101: Invigorate Your Knowledge of Targeted Protein DegradationGwenn M. Hansen, Ph.D., CSO, Nurix8:30 a.m. ET Wednesday, October 27Oral Session: Clinical Update on Degraders in the Clinic, Key Learnings & Future DirectionsTurning Degraders into Drugs – NX-2127 & NX-5948Arthur T. Sands, M.D., Ph.D., President and CEO11:45 a.m. ET Panel Discussion: The Next Wave of Therapeutics: Applications of Protein Degradation for Oncology & BeyondArthur T. Sands, M.D., Ph.D.12:15 p.m. ET Thursday, October 28Panel Discussion: Expanding Diversity & Inclusion in Targeted Protein Degradation FieldGwenn M. Hansen, Ph.D.9:30 a.m. ET About Nurix Therapeutics, Inc.Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurixtx.com/. Forward Looking StatementThis press release contains statements ...